Formerly known as idiopathic thrombocytopenic purpura, immune thrombocytopenia (ITP) is an acquired autoimmune condition characterized by increased platelet destruction and impaired platelet ...

The FDA also approved Doptelet Sprinkle oral granules for use in children aged 1 to less than 6 years. The Food and Drug Administration (FDA) has approved Doptelet ® (avatrombopag) for the treatment ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

While immune thrombocytopenia (ITP) can occur in both adults and children, what makes pediatric ITP most distinct from adult ITP is the high rate of children who improve on their own, noted James ...

Based on 2 randomized, placebo-controlled studies, the FDA approved romiplostim (Nplate) for pediatric patients 1 year and older with immune thrombocytopenia (ITP) for at least 6 months who do not ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

The Food and Drug Administration has approved Nplate for pediatric patients 1 year of age and older with immune thrombocytopenia who have had an insufficient response to medications, such as ...

Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms. Pediatric patients with systemic lupus erythematosus (SLE) ...

Association of severe thrombocytopenia related to increased destruction of platelets and administration of AMD has recently been reported (J Pediatr 104:611, 1985). To investigate the etiology of this ...

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...